{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:00Z","timestamp":1791475500728,"version":"4.3.4"},"reference-count":70,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anemia is a hallmark of chronic kidney disease (CKD), worsens with disease progression, and profoundly affects a patient's well-being. Major pathogenic factors are inadequate kidney erythropoietin (EPO) production and absolute and functional iron deficiency. The 2 mainstays of current anemia treatment are a) replacement therapy with recombinant EPO or 1 of its glycosylated derivatives, administered subcutaneously or intravenously, and b) intravenous (IV) iron injections. Over the past 5 years, hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitors (HIF-PHIs) have been approved in many countries for the management of anemia in both nondialysis and dialysis-dependent patients with CKD. Due to cardiovascular safety concerns, only 2 HIF-PHIs, daprodustat and vadadustat, have been approved for marketing in the United States, and only for patients on maintenance dialysis. HIF-PHIs are oral agents that are effective at improving and maintaining hemoglobin levels by activating HIF signaling in anemic patients with CKD. They stimulate the production of endogenous EPO, increase total iron-binding capacity through their direct effects on transferrin gene transcription, lower plasma hepcidin indirectly, and have beneficial effects on red blood cell parameters. Here, we discuss the mechanisms of action and pharmacologic properties of different HIF-PHIs. We discuss unwanted on-target and off-target effects, review cardiovascular and other safety concerns, and provide a benefit\/risk-based perspective on how this new class of oral drugs might impact current anemia management in CKD. A clinical case is presented that highlights the clinical complexities and therapeutic challenges in managing anemia in CKD.<\/jats:p>","DOI":"10.1182\/hematology.2024000655","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:04:16Z","timestamp":1733497456000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease"],"prefix":"10.1182","volume":"2024","author":[{"given":"Volker H.","family":"Haase","sequence":"first","affiliation":[{"name":"1 Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt University School of Medicine, Nashville, TN"},{"name":"2 Medical and Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"3 Department of Nephrology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Koury","sequence":"additional","affiliation":[{"name":"2 Medical and Research Service, Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN"},{"name":"4 Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt University School of Medicine, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2024122013160221100_hem2024000655C1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"2024122013160221100_hem2024000655C2","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease Improving Global Outcomes Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2024122013160221100_hem2024000655C3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2013.21","article-title":"Anaemia management and mortality risk in chronic kidney disease","volume":"9","author":"Horl","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2024122013160221100_hem2024000655C4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"key":"2024122013160221100_hem2024000655C5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"2024122013160221100_hem2024000655C6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"issue":"11","key":"2024122013160221100_hem2024000655C7","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1681\/ASN.2022040413","article-title":"Hypoxia-inducible factor\u2013prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs?","volume":"33","author":"Locatelli","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2024122013160221100_hem2024000655C8","unstructured":"Food and Drug Administration. Daprodustat prescribing information. Accessed 20July2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216951s000lbl.pdf."},{"key":"2024122013160221100_hem2024000655C9","unstructured":"Food and Drug Administration. Vadadustat prescribing information. Accessed 20July2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215192s000lbl.pdf."},{"key":"2024122013160221100_hem2024000655C10","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2024122013160221100_hem2024000655C11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2024122013160221100_hem2024000655C12","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"2024122013160221100_hem2024000655C13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2215\/CJN.00550122","article-title":"Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: a phase 3 randomized, double-blind, noninferiority trial","volume":"17","author":"Coyne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024122013160221100_hem2024000655C14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"key":"2024122013160221100_hem2024000655C15","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"2024122013160221100_hem2024000655C16","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"key":"2024122013160221100_hem2024000655C17","doi-asserted-by":"crossref","first-page":"e13826","DOI":"10.1111\/apha.13826","article-title":"EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis","volume":"235","author":"Kobayashi","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"key":"2024122013160221100_hem2024000655C18","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking Hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"2024122013160221100_hem2024000655C19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.34067\/KID.0000092020","article-title":"Mannose binding lectin is hydroxylated by collagen prolyl-4-hydroxylase and inhibited by some PHD inhibitors","volume":"1","author":"Bhute","year":"2020","journal-title":"Kidney360"},{"issue":"4","key":"2024122013160221100_hem2024000655C20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.kint.2017.03.008","article-title":"Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor","volume":"92","author":"Kiriakidis","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"2024122013160221100_hem2024000655C21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"S6","key":"2024122013160221100_hem2024000655C22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/BF02332176","article-title":"Divergent regulation of vascular endothelial growth factor and of erythropoietin gene expression in vivo","volume":"431","author":"Sandner","year":"1996","journal-title":"Pflug Arch"},{"issue":"6","key":"2024122013160221100_hem2024000655C23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"2024122013160221100_hem2024000655C24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis","volume":"20","author":"Bailey","year":"2019","journal-title":"BMC Nephrol"},{"key":"2024122013160221100_hem2024000655C25","doi-asserted-by":"crossref","first-page":"e82952","DOI":"10.1371\/journal.pone.0082952","article-title":"Association between ischemic stroke and iron-deficiency anemia: a population-based study","volume":"8","author":"Chang","year":"2013","journal-title":"PLoS One"},{"key":"2024122013160221100_hem2024000655C26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3324\/haematol.2019.245092","article-title":"Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats","volume":"106","author":"Jimenez","year":"2021","journal-title":"Haematologica"},{"key":"2024122013160221100_hem2024000655C27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2018893099","article-title":"Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis","volume":"134","author":"Parrow","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2024122013160221100_hem2024000655C28","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2007-04-087593","article-title":"Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2\/4","volume":"110","author":"Lin","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2024122013160221100_hem2024000655C29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ajh.26644","article-title":"Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease","volume":"97","author":"Koury","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"2024122013160221100_hem2024000655C30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCRESAHA.119.316453","article-title":"Iron-deficiency and estrogen are associated with ischemic stroke by up-regulating transferrin to induce hypercoagulability","volume":"127","author":"Tang","year":"2020","journal-title":"Circ Res"},{"issue":"9","key":"2024122013160221100_hem2024000655C31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.thromres.2019.07.013","article-title":"The stimulation of thrombosis by hypoxia","volume":"181","author":"Gupta","year":"2019","journal-title":"Thromb Res"},{"issue":"4","key":"2024122013160221100_hem2024000655C32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/cdd.2008.21","article-title":"The role of hypoxia-inducible factors in tumorigenesis","volume":"15","author":"Rankin","year":"2008","journal-title":"Cell Death Differ"},{"issue":"11","key":"2024122013160221100_hem2024000655C33","doi-asserted-by":"crossref","first-page":"e159839","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"2024122013160221100_hem2024000655C34","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1172\/JCI120855","article-title":"Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers","volume":"129","author":"Chappell","year":"2019","journal-title":"J Clin Investig"},{"key":"2024122013160221100_hem2024000655C35","unstructured":"Food and Drug Administration. Belzutifan prescribing information. Accessed 20July2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215383s006lbl.pdf."},{"issue":"3","key":"2024122013160221100_hem2024000655C36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2006-939441","article-title":"Vascular complications in Chuvash polycythemia","volume":"32","author":"Gordeuk","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"2024122013160221100_hem2024000655C37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HP.S130526","article-title":"Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer","volume":"5","author":"Seeley","year":"2017","journal-title":"Hypoxia (Auckl)"},{"issue":"6","key":"2024122013160221100_hem2024000655C38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/1091581817737232","article-title":"Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats","volume":"36","author":"Beck","year":"2017","journal-title":"Int J Toxicol"},{"issue":"2","key":"2024122013160221100_hem2024000655C39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0192623319880445","article-title":"Carcinogenicity assessment of daprodustat (GSK1278863), a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor","volume":"48","author":"Adams","year":"2020","journal-title":"Toxicol Pathol"},{"key":"2024122013160221100_hem2024000655C40","doi-asserted-by":"crossref","first-page":"109524","DOI":"10.1016\/j.cellsig.2020.109524","article-title":"Role of oxygen and the HIF-pathway in polycystic kidney disease","volume":"69","author":"Buchholz","year":"2020","journal-title":"Cell Signal"},{"issue":"6","key":"2024122013160221100_hem2024000655C41","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.devcel.2009.11.008","article-title":"The role of hypoxia in development of the mammalian embryo","volume":"17","author":"Dunwoodie","year":"2009","journal-title":"Dev Cell"},{"issue":"62","key":"2024122013160221100_hem2024000655C42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cophys.2018.12.003","article-title":"Revisiting the role of hypoxia-inducible factors in pulmonary hypertension","volume":"7","author":"Shimoda","year":"2019","journal-title":"Curr Opin Physiol"},{"issue":"4","key":"2024122013160221100_hem2024000655C43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"2024122013160221100_hem2024000655C44","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s00125-011-2081-0","article-title":"Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells","volume":"54","author":"Lin","year":"2011","journal-title":"Diabetologia"},{"key":"2024122013160221100_hem2024000655C45","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ndt\/gfl716","article-title":"Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients","volume":"22","author":"Rossert","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2024122013160221100_hem2024000655C46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12882-015-0138-x","article-title":"Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients","volume":"16","author":"Sibbel","year":"2015","journal-title":"BMC Nephrol"},{"key":"2024122013160221100_hem2024000655C47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"Luo","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2024122013160221100_hem2024000655C48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12882-019-1554-0","article-title":"In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study","volume":"20","author":"Ingrasciotta","year":"2019","journal-title":"BMC Nephrol"},{"key":"2024122013160221100_hem2024000655C49","doi-asserted-by":"crossref","first-page":"e0277921","DOI":"10.1371\/journal.pone.0277921","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study","volume":"17","author":"Narita","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"2024122013160221100_hem2024000655C50","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000523947","article-title":"Resistance to Erythropoiesis-stimulating agents among patients on hemodialysis is typically transient","volume":"53","author":"Goodkin","year":"2022","journal-title":"Am J Nephrol"},{"issue":"12","key":"2024122013160221100_hem2024000655C51","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"2024122013160221100_hem2024000655C52","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/ndt\/gfq802","article-title":"Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study","volume":"26","author":"Panichi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2024122013160221100_hem2024000655C53","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1093\/ndt\/gfs007","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients","volume":"27","author":"Minutolo","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2024122013160221100_hem2024000655C54","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000358215","article-title":"Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients","volume":"37","author":"Okazaki","year":"2014","journal-title":"Blood Purif"},{"issue":"4","key":"2024122013160221100_hem2024000655C55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pds.3755","article-title":"Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study","volume":"24","author":"Gillespie","year":"2015","journal-title":"Pharmacoepidemiol Drug"},{"issue":"1","key":"2024122013160221100_hem2024000655C56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kisu.2020.12.006","article-title":"Treatment of anemia in difficult-to-manage patients with chronic kidney disease","volume":"11","author":"Raichoudhury","year":"2021","journal-title":"Kidney Int Suppl"},{"issue":"4","key":"2024122013160221100_hem2024000655C57","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0272-6386(03)00915-6","article-title":"Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients","volume":"42","author":"Kalantar-Zadeh","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2024122013160221100_hem2024000655C58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1080\/08860220903082606","article-title":"Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation","volume":"31","author":"Malyszko","year":"2009","journal-title":"Ren Fail"},{"key":"2024122013160221100_hem2024000655C59","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ndt\/gfn543","article-title":"Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients","volume":"24","author":"Bradbury","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2024122013160221100_hem2024000655C60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2369-12-67","article-title":"Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors","volume":"12","author":"Inrig","year":"2011","journal-title":"BMC Nephrol"},{"key":"2024122013160221100_hem2024000655C61","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1038\/s41598-017-04664-y","article-title":"Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"2024122013160221100_hem2024000655C62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.medici.2017.03.001","article-title":"Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients","volume":"53","author":"Petrulien\u0117","year":"2017","journal-title":"Medicina"},{"issue":"3","key":"2024122013160221100_hem2024000655C63","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.xkme.2020.01.007","article-title":"Inflammation and Erythropoiesis-stimulating agent response in hemodialysis patients: a self-matched longitudinal study of anemia management in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"2","author":"Karaboyas","year":"2020","journal-title":"Kidney Med"},{"issue":"2","key":"2024122013160221100_hem2024000655C64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000438870","article-title":"Minor elevation in C-reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients","volume":"131","author":"Kimachi","year":"2015","journal-title":"Nephron"},{"issue":"7","key":"2024122013160221100_hem2024000655C65","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: Sierras study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"suppl 1","key":"2024122013160221100_hem2024000655C66","article-title":"#2063 safety and efficacy of vadadustat vs darbepoetin alfa in patients on maintenance dialysis by prespecified subgroups of baseline ESA dose","volume":"39","author":"Chertow","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"2024122013160221100_hem2024000655C67","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s11739-021-02738-4","article-title":"Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation","volume":"16","author":"Zhou","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"suppl 2","key":"2024122013160221100_hem2024000655C68","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2024122013160221100_hem2024000655C69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2015","journal-title":"Ren Replace Ther"},{"key":"2024122013160221100_hem2024000655C70","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/409\/2346505\/409haase.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/409\/2346505\/409haase.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:16:28Z","timestamp":1734700588000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/409\/526198\/Hypoxia-inducible-factor-activators-a-novel-class"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000655","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}